ivermectin oral / Generic mfg. - LARVOL DELTA

HX06 A Japanese therapeutic hole in one! (PubMed, Br J Dermatol) - "From golf course dirt to global health hero, ivermectin proves that sometimes, the best medical breakthroughs are hiding under our feet - just waiting for the right scientist to tee them up. This 'mitey drug' has once again proven its worth, offering hope and effective care for patients of all ages, ethnicities and backgrounds battling scabies - a disease that knows no boundaries."

Journal • Review • Dermatology • Infectious Disease • Ophthalmology

British Society for Skin Care in Immunosuppressed IndividualsOral presentationsBI01 Persistent nonpruritic scabies in a patient on nemolizumab for the treatment of prurigo nodularis. (PubMed, Br J Dermatol) - P3 | "The patient did not respond to monotherapy with topical permethrin 5% (and standard hot wash measures) and required a combination of oral ivermectin and topical permethrin 5% for complete clearance. Allergy 2019; 74: 1727-37). It is important to consider the potential absence of pruritus in patients on nemolizumab when assessing new cutaneous and systemic presentations, particularly in the context of a rising prevalence of scabies in the UK."

Journal • Allergy • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Infectious Disease • Prurigo Nodularis • Pruritus • POSTN • TSLP

PA01 Treating scabies with oral ivermectin in infants: series of 12 cases. (PubMed, Br J Dermatol) - "Early treatment with oral ivermectin should be emphasized, along with reiteration of the importance of treating contacts to reduce chances of recurrence. Additionally, existing data suggest that oral ivermectin in children weighing < 15 kg is safe, which is also supported by our study."

Journal • Retrospective data • Atopic Dermatitis • CNS Disorders • Dermatology • Epilepsy • Immunology • Infectious Disease • Pruritus

GD11 Scabies in the Mid-West of Ireland: trends and practices in primary care. (PubMed, Br J Dermatol) - "Difficulties with treatment failure and difficulty sourcing treatment options are concerns. We have developed a scabies educational care bundle disseminated to GPs in our hospital group's catchment area and plan to assess the impact of this on referral to dermatology services for scabies management."

Journal • Retrospective data • Dermatology • Infectious Disease

BI36 A case study of hypereosinophilic syndrome in a patient with atopic dermatitis on dupilumab therapy and Strongyloides infection. (PubMed, Br J Dermatol) - "Despite topical treatments and ciclosporin, his eczema persisted, leading to the initiation of dupilumab...This is a case of hypereosinophilic syndrome with colitis secondary to dupilumab in a patient with positive Strongyloides serology. This case demonstrates the diagnostic difficulty in Strongyloides-positive patients, given that both hypereosinophilic syndrome and Strongyloides hyperinfection can present with colitis, and there is a theoretical risk of disseminated Strongyloides and hyperinfection in patients immunosuppressed with dupilumab."

Journal • Asthma • Atopic Dermatitis • Dermatitis • Dermatology • Eosinophilia • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Hypereosinophilic Syndrome • Immunology • Infectious Disease • Metabolic Disorders • Oncology • Pain • Pulmonary Disease • Respiratory Diseases

Synergistic potential of Ivermectin and doxorubicin in oral squamous cell carcinoma: an in vitro investigation. (PubMed, BMC Pharmacol Toxicol) - No abstract available

Journal • Preclinical • Oncology • Oral Cancer • Squamous Cell Carcinoma

Patent Pulmonary Infection with the Invasive Pentastomid Raillietiella orientalis in a Panther Chameleon (Furcifer pardalis) in Belgium. (PubMed, Animals (Basel)) - "This case provides the second description of R. orientalis in a chameleon definitive host and highlights the parasite's capacity for phenotypic plasticity in host utilization. Our findings underscore the potential role of the international reptile trade in facilitating the introduction and dissemination of this invasive pentastomid in Europe."

Journal • Anorexia • Infectious Disease • Respiratory Diseases

PCV2 Cap protein nuclear import via importin α/β receptor: molecular insights and antiviral potential. (PubMed, Front Microbiol) - "While ivermectin (IVM) only impedes transport without affecting viral replication. These findings provide significant insights into the molecular mechanisms of PCV2-Cap nuclear import and highlight potential therapeutic targets for antiviral strategies aimed at disrupting viral capsid transport."

Journal • Infectious Disease

Retrospective Analysis of the Use of Oral Ivermectin and 5% Permethrin Cream in Galicia (Spain). (PubMed, Basic Clin Pharmacol Toxicol) - No abstract available

Journal • Retrospective data

Comparative pharmacokinetic and bioequivalence of nine oral ivermectin formulations in dogs. (PubMed, J Vet Sci) - "All formulations achieved plasma concentrations sufficient for prophylaxis, but only B, C, and G satisfied bioequivalence criteria. Larger sample sizes and standardized evaluation guidelines are recommended for multi-formulation bioequivalence studies."

Clinical • Journal • PK/PD data

Strongyloides stercoralis hyperinfection with thrombosis: A systematic review of case reports. (PubMed, New Microbes New Infect) - "Ivermectin was the mainstay of therapy, alone or with albendazole, although treatment regimens were inconsistently reported...Early empiric antiparasitic therapy, timely investigation for thrombotic complications, and individualized anticoagulation strategies are essential to improving outcomes. Given the reliance on case-level evidence, prospective studies and standardized reporting are urgently needed to characterize better risk factors, optimal management, and prognosis of this neglected but critical complication."

Journal • Review • Cardiovascular • Hematological Disorders • Infectious Disease • Pulmonary Embolism • Respiratory Diseases • Septic Shock • Thrombosis

Effectiveness of Oral Ivermectin Treatment in Cases Unresponsive to Classical Demodex Blepharitis Treatment. (PubMed, Turkiye Parazitol Derg) - "OSDI scoring mean ± SD values before classical Demodex blepharitis treatment and after oral ivermectin treatment were 77.47±5.74 and 6.69±4.71, respectively. In the treatment of Demodex related blepharitis, the use of oral ivermectin is an effective treatment option in cases that do not respond to classical treatment."

Journal • Dry Eye Disease • Ocular Inflammation • Ophthalmology • Seborrheic Dermatitis

Subcutaneous ivermectin treatment in severe strongyloidiasis: is it time to recommend drug concentration measurements and parasitological stool monitoring follow-up? (PubMed, J Travel Med) - "Subcutaneous veterinary formulations of ivermectin (IVM) may be the only option for severe treatment, but the dosage and duration are empirical. This article, based on a clinical case, discusses ivermectin concentrations and proposes clinical and parasitological follow-up to guide parenteral therapy in severe strongyloidiasis."

Journal • Infectious Disease

Bound by tradition: severe pediculosis capitis in a breastfeeding mother with religious headwear. (PubMed, Skin Health Dis) - "Treatment with permethrin 1% lotion and weekly oral ivermectin for 4 weeks, in conjunction with broad-spectrum antibiotics and supportive care, resulted in near-complete eradication. This case represents one of the most severe presentations of pediculosis capitis documented, demonstrating how cultural practices can impede early detection and complicate management."

Journal • Dermatology • Pruritus

Therapeutic and Formulation Advances of Ivermectin in Veterinary and Human Medicine. (PubMed, Pharmaceutics) - "Given its primary application in veterinary medicine, there is a need to enhance the development of dosage forms suitable for human use. Therefore, this review details the discovery, mechanisms, and applications of IVM, while also examining the challenges of resistance, side-effects, and controversy surrounding its use, to ultimately emphasize the importance of targeted, optimized IVM delivery via tailored dosage form development in animals and humans as part of the One Health approach to interlink innovations across veterinary and human medicine fields."

Journal • Review • Dermatology • Gastrointestinal Disorder • Infectious Disease • Rosacea

Repurposing Ebselen for a potential blending-based therapeutic strategy against gastrointestinal nematodes of small ruminants. (PubMed, Res Vet Sci) - "The combination of Ebselen and IVM resulted in a statistically significant increase in larval migration inhibition, demonstrating a synergistic effect (>30 %). The data confirm the use of Ebselen and IVM in a novel blending-based therapeutic strategy to manage GIN that affects small ruminants."

Journal • Infectious Disease

Efficacy and safety of oral ivermectin versus benzyl benzoate for the treatment of scabies: a systematic review and meta-analysis of randomized controlled trials. (PubMed, Front Med (Lausanne)) - "However, ivermectin's significantly better safety and tolerability, combined with the practical advantage of oral administration, establish it as a valuable and often preferable therapeutic choice. CRD420251143937."

Journal • Retrospective data • Review • Dermatology • Infectious Disease • Pruritus

Assessing the diagnostic value of qPCR for Trichuris trichiura: sub-analysis of a multi-country clinical trial to determine the efficacy of albendazole compared to an albendazole-ivermectin fixed dose combination. (PubMed, Front Parasitol) - P2/3 | "Machine learning models showed good performance for predicting baseline infection intensity. While not interchangeable, qPCR complements KK and enhances the precision of drug efficacy evaluation in helminth clinical trials."

Journal • Infectious Disease

Ivermectin to reduce malaria transmission- safety and efficacy results from the BOHEMIA cluster randomized trial in Mozambique. (PubMed, EClinicalMedicine) - P3 | "As per protocol, we planned to randomise 53 clusters per arm (1:1:1), to receive either (a) single 400 mcg/kg dose of ivermectin to all eligible humans, once a month for three months, (b) the same ivermectin treatment to eligible humans plus injectable ivermectin (1% solution) to all eligible pigs (300 mcg/kg) and cattle (200 mcg/kg) in the cluster once a month for three months or (c) albendazole (400 mg), to serve as control, to eligible humans, following the same schedule...Additionally, valuable data regarding safety were collected (ClinicalTrials.gov number, NCT04966702). The study was funded and supported by Unitaid under the "BOHEMIA" grant."

Journal • Infectious Disease • Malaria

Rare Case of Pulmonary Infection with Multiple Parasites: Diagnostic Challenges and Lessons Learned (APSR 2025) - "He was treated with oral ivermectin for two days, which resulted in clinical improvement and resolution of findings on follow-up CT imaging. He was subsequently discharged and prescribed a seven-day course of albendazole, with further clinical improvement observed at follow-up...Risk factors are often overlooked but play a crucial role in guiding diagnosis. This case highlights the importance of maintaining a high index of suspicion and employing a comprehensive diagnostic approach to effectively identify and manage parasitic lung diseases."

Clinical • Cough • Gastric Cancer • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Solid Tumor

Performance of novel onchocerciasis rapid diagnostic tests in a field setting in South Sudan. (PubMed, PLoS Negl Trop Dis) - "O. volvulus and Mansonella spp. prevalence was high among pregnant and post-partum women in Maridi. The novel RDTs demonstrated sensitivities within the range of the commercially available Ov16 SD Bioline RDT, meeting the WHO threshold for onchocerciasis mapping but not for MDA stopping decisions. No RDT met the specificity threshold of 99.8%, although some exhibited slightly higher specificity than Ov16 SD Bioline RDT. This suboptimal specificity raises concerns, underscoring the need for better diagnostic tools to support onchocerciasis elimination efforts."

Journal • Infectious Disease

Ivermectin for Kidney Cancer: Patients Have Questions, Clinicians Have Concerns-Kidney cancer specialists struggle to be supportive but also honest with patients (MedPageToday) - "'The number one question that I'm asked by patients is 'I hear how ivermectin and bendazoles are going to cure kidney cancer. How should I incorporate this into my treatment?' said Matthew Campbell, MD..."

Media quote

Ivermectin attenuates Schistosoma japonicum-induced liver fibrosis and is associated with downregulation of YAP signaling. (PubMed, Front Cell Infect Microbiol) - "It also reduced arginase-1 and profibrotic markers in Kupffer cells and decreased profibrotic factor secretion in coculture assays. These results demonstrate that ivermectin attenuates S. japonicum-induced liver fibrosis and modulates YAP signaling as well as profibrotic activity, highlighting its therapeutic potential in S. japonicum infection."

Journal • Fibrosis • Immunology • Infectious Disease • Liver Cirrhosis

Efficacy of combination therapy with oral Ivermectin and topical permethrin versus permethrin monotherapy in pediatric patients with persistent scabies: a propensity score-adjusted observational study. (PubMed, BMC Infect Dis) - "In this study adding two oral doses of ivermectin to standard permethrin shortened symptom resolution time, raised cure rates, and halved recurrences, with only modest rise in transient mild AEs. Future randomised trials should couple efficacy with cost-effectiveness analyses and evaluate policy options-generic licensure, unit-tablet dispensing, and insurance reimbursement-to ensure equitable access to this regimen."

Journal • Monotherapy • Observational data • Dermatology • Infectious Disease • Pain • Pediatrics • Pruritus

WITHDRAWN Persistence of onchocerciasis in Cameroon 5 years from the 2030 roadmap goal: urgent alternatives needed (ASTMH 2025) - "A marked rebound in parasitological indicators was observed in hotspot communities in Massangam five years post-ATS cessation compared to baseline levels (p: 0.04), and in sentinel communities in Yabassi, the prevalence remained almost unchanged after ten additional rounds of ivermectin treatment, decreasing from 43.8% (95% CI: 37.7% – 50.1%) to 38.8% (95% CI: 33.0% – 45.0%) (p: 0.222). These findings raise concerns about the potential resistance of O. volvulus and suggest that ivermectin alone may not be enough to achieve elimination goals, calling for the introduction of targeted, coordinated and sustained ATS to reach the 2030 goals."

Infectious Disease